Healthy Returns: AbbVie is the newest potential weight loss drug market player
AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra’s obesity drug. AI takes center stage at HIMSS ...
AbbVie Steps Into The Ring In The Obesity Drug Wars
AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...
Makary’s moment in HELP awaits
Dr. Marty Makary, President Donald Trump’s pick to lead the FDA, will face the lawmakers standing between him and Senate ...
PharmiWeb7h
AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
AbbVie (NYSE: ABBV) and Gubra A/S (CPSE:GUBRA), a company specializing in preclinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases, today ...
AbbVie price target raised to $223 from $200 at BofA
BofA raised the firm’s price target on AbbVie (ABBV) to $223 from $200 and keeps a Neutral rating on the shares after the company and Gubra ...
Pharmabiz16h
AbbVie and Gubra ink license agreement to develop an amylin analog for the treatment of obesity
AbbVie and Gubra ink license agreement to develop an amylin analog for the treatment of obesity: North Chicago, Illinois Tuesday, March 4, 2025, 10:00 Hrs [IST] AbbVie and Gubra A ...
BioWorld21h
Abbvie enters $2.2B deal for Gubra’s amylin obesity drug
Abbvie Inc. is buying into the obesity fray in a potential $1.875 billion development and commercialization agreement with ...
Investor's Business Daily on MSN23h
AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.
AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based ...
AbbVie enters obesity treatment via Gubra licensing agreement
AbbVie (ABBV) is entering into the weight-loss space after partnering with Gubra through a licensing agreement. Market Domination's Julie Hyman and Josh Lipton break down this possible alternative to ...